iTeos Therapeutics, Inc. revenue for the last year amounted to 12.60 M USD, the most of which — 12.60 M USD — came from its highest performing source at the moment, Cancer Immunotherapies, the year earlier bringing 267.63 M USD. The greatest contribution to the revenue figure was made by United States and Belgium — last year it brought iTeos Therapeutics, Inc. 12.60 M USD, and the year before that — 267.63 M USD.